The US president says the levies on pharmaceutical imports are imminent, but won’t take effect for a year to a year and a ...

Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly ...

In the second part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, outlines how the ...

Amid the push for reshoring and fiscal reform, the tariffs are part of a broader effort to rebalance trade and fund domestic ...

Bruce Leuchter, CEO, Neurvati, explains why aligning drug development with patient-reported outcomes is key to demonstrating value and achieving payer alignment in the rare disease space.

In the first part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan ...

A qualitative study explores how MA plan leaders, kidney care managers, and dialysis providers perceive the benefits, risks, ...

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...

Bruce Leuchter, CEO, Neurvati, discusses why patient engagement is essential to understanding rare diseases and driving the ...

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

The Impact of FDA’s Ban on Compounded GLP-1s A Pharmaceutical Executive article explores how the FDA’s ban on compounded semaglutides—following stabilized supply from Novo Nordisk and Eli Lilly—has ...

Classic and recent examples Classic examples illustrate the application of these strategies. For instance, Cialis (tadalafil) is marketed for erectile dysfunction, while Adcirca (also tadalafil) is ...